Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/102822/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life (Protocol)

Al-Assaf AS, Denton DA, Abraham RP, Rutjes AWS, Chong LY, Anderson JL, Malik MA, Tabet N

Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life.
Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD011906.
DOI: 10.1002/14651858.CD011906.

www.cochranelibrary.com
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>HEADER</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>2</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>4</td>
</tr>
<tr>
<td>METHODS</td>
<td>4</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>7</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>8</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>13</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF AUTHORS</td>
<td>20</td>
</tr>
<tr>
<td>DECLARATIONS OF INTEREST</td>
<td>20</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>21</td>
</tr>
</tbody>
</table>

---

Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life (Protocol)  
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life**

Aalya S Al-Assaf\(^1\), David A Denton\(^2\), Rajesh P Abraham\(^3\), Anne WS Rutjes\(^4,5\), Lee Yee Chong\(^6\), John L Anderson\(^1\), Muzaffar A Malik\(^7\), Naji Tabet\(^8\)

\(^1\) Division of Medical Education, Brighton and Sussex Medical School, University of Brighton, Falmer, UK. \(^2\) Specialist Older People’s Services, Sussex Partnership NHS Foundation Trust, Uckfield, UK. \(^3\) Old Age Psychiatry, Cognitive Treatment and Research Unit, Sussex Partnership NHS Foundation Trust, Crowborough, UK. \(^4\) Centre for Systematic Reviews, Fondazione “Università G. D’Annunzio”, Chieti, Italy. \(^5\) Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. \(^6\) UK Cochrane Centre, Oxford, UK. \(^7\) Department of Medical Education (Postgraduate), Brighton and Sussex Medical School, University of Brighton, Falmer, UK. \(^8\) Postgraduate Medicine, Brighton and Sussex Medical School, Brighton, UK.

**Contact address:** Naji Tabet, Postgraduate Medicine, Brighton and Sussex Medical School, Mayfield House, University of Brighton, Falmer, Brighton, BN1 9PH, UK. N.T.Tabet@bton.ac.uk.

**Editorial group:** Cochrane Dementia and Cognitive Improvement Group.

**Publication status and date:** New, published in Issue 10, 2015.

**Citation:** Al-Assaf AS, Denton DA, Abraham RP, Rutjes AWS, Chong LY, Anderson JL, Malik MA, Tabet N. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD011906. DOI: 10.1002/14651858.CD011906.

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**ABSTRACT**

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To evaluate the effects of vitamin and mineral supplementation on cognitive function in cognitively healthy people in late life.
BACKGROUND

Description of the condition

Cognitive health, mild cognitive impairment and dementia

Cognitively healthy or successful cognitive ageing can be defined as “not just the absence of cognitive impairment, but the development and preservation of the multi-dimensional cognitive structure that allows the older adult to maintain social connectedness, and ongoing sense of purpose, and the abilities to function independently, to permit functional recovery from illness and injury, and to cope with residual cognitive deficits”, but there is no broad consensus on a definition yet (Depp 2012; Hendrie 2006). Successful cognitive ageing is distinct from mild cognitive impairment (MCI) and dementia. Dementia is a syndrome of cognitive and functional decline that is usually progressive. Although most commonly associated with forgetfulness, memory is not the only function that is affected. Other higher cortical functions such as orientation, comprehension, learning, language and judgement are often affected.

In most cases, the onset of dementia is gradual. In the early stages of the illness, cognitive deficits are relatively mild, but still affect the ability to perform some normal daily activities. As the syndrome progresses, those affected become increasingly dependent on others for all activities of daily living. Prior to the onset of the disease, there is usually a stage of mild cognitive impairment (MCI) when cognitive deficits beyond those of normal ageing are detectable, but ordinary activities are not significantly affected.

Types of MCI and dementia

There are numerous different definitions of MCI, with different focus (e.g., neuropsychological impairment such as memory versus non-memory) (Matthews 2007), prevalence (Stephan 2007), and risk of progression to dementia (Matthews 2008). Further subdivisions can be made depending on the suspected underlying cause of cognitive deficits and this has led to the distinction between MCI due to Alzheimer’s disease and MCI due to vascular disease (termed ‘vascular cognitive impairment no dementia’: VCIND). Moreover, attempts have been made to develop new criteria to capture early preclinical states including, for example, pre-MCI that captures individuals with impaired executive function and language, higher apathy scores, and lower left hippocampal volumes compared to normal controls (Duara 2011). Still, there is no standardised definition of MCI accepted for use in clinical trials (Christa Maree Stephan 2013), but adaptations of the criteria suggested by Petersen 1999 are commonly used.

Subtypes of dementia are distinguished by the underlying pathology. The four most common subtypes are Alzheimer’s disease dementia (AD) (accounting for an estimated 60% to 70% of all dementia cases); vascular dementia (VaD); dementia with Lewy Bodies (DLB); and frontotemporal dementia (FTD). Accurate diagnosis of the subtypes may be difficult. Mixed pathology is common, with more than 80% of cases having some features of Alzheimer’s disease (Jellinger 2006; WHO 2012). However, the proportion of dementia attributable to Alzheimer’s disease reduces with age (Savva 2009).

Prevalence of MCI and dementia

In the UK Medical Research Council’s population-based Cognitive Function and Ageing Study (CFAS), when 18 different definitions of MCI were mapped the range of prevalence estimates was found to be variable (0.1% to 42.0%), and conversion rates to dementia generally low (Stephan 2007). However, prevalence and conversion rates in specialist settings have been reported to be higher than population-based studies (adjusted conversion rate from MCI to dementia 9.6% versus 4.9%) (Mitchell 2009).

The risk of dementia increases with age; according to a World Health Organization (WHO) report, only 2% to 10% of cases start before the age of 65 (WHO 2012). The same report estimated that there were 35.6 million people with dementia in the world in 2010, and that this figure would double every 20 years to reach 65.7 million in 2030 (WHO 2012). However, there is a degree of uncertainty about the expected increase in prevalence of dementia. Recent CFAS research by Matthews 2013, and by Christensen 2013 on work in Denmark suggests that age-specific prevalence of dementia may be reducing in developed countries which supports the possibility that there may be modifiable risk factors. Nevertheless, because of population ageing, the overall prevalence continues to rise.

Risk factors

Generally, risk factors of dementia can be divided into modifiable and non-modifiable factors: the non-modifiable risk factors include age, genetic factors, family history, gender (females are at higher risk), and Down syndrome. The modifiable factors are smoking (both current and past smoking), high cholesterol, stroke, hypertension, lack of physical activity, diabetes mellitus, obesity, and low educational level. Among the non-modifiable risk factors, age is found to be the most significant one. It has been indicated that, in people who are older than 65 years, the risk of AD (the most typical cause of dementia) doubles every five years (Launer 1999; McCullagh 2001; van den Berg 2012; van der Flier 2005). A pooled analysis of four prospective studies in Europe has revealed that the incidence rate of AD among people aged 90 and over was 63.5/1000 person-year (Launer 1999).

Although age is the strongest risk factor, other risk factors for AD have been identified. Genetics plays a major role in early onset AD, but a lesser role in the much commoner late onset disease. Epidemiological evidence suggests that AD shares many risk factors with vascular disease, including diabetes, midlife obesity, midlife hypertension, smoking and physical inactivity (WHO 2012; World Alzheimer Report 2014). The possible mechanism of cognitive decline in late life (also referred to as ‘old age’) is thought to be due to decreasing co-ordination between different cortical regions which work for the higher level cognitive functions. Such changes in brain function may have a role in some physiological disorders like hypertension, for instance, which is also a risk factor for cognitive decline (Bishop 2010; O’Sullivan 2001).

At present there is no cure for any subtype of dementia, but the identification and targeting of modifiable risk factors may offer opportunities to modify its onset and course. Research is showing that cognitive stimulation, exercise, diet, and the management of vascular risk factors such as hypertension, diabetes, obesity, smoking, and physical inactivity may have an important role in prevention of AD (Lindsay 2002; Lourida 2013; Norton 2014; Wilson 2002). There is evidence that vitamins such as vitamin B12 and...
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life (Protocol)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Vitamins and minerals are involved in thousands of intracellular and extracellular mechanisms in the CNS. Specific functions differ according to the type of molecules and compounds involved. These activities can be classified into a number of roles that support homeostasis and create an ideal environment for neuronal health. This may help maintain brain and cognitive reserve which in turn may impact the rate of decline of those most at risk of dementia. Brain and cognitive reserve, developed early in life and consolidated in mid life, may buffer the expression of symptoms of dementia in the presence of neurodegenerative disease (Casserly 2004).

**Vitamins:**

Vitamin A may be involved in the stabilisation of beta amyloid fibrils (Ono 2012). Vitamin D has been implicated as a precursor of hormones required for calcium and phosphorus metabolism and also potentially has a role in cognition in older adults (Przybylski 2007). Vitamin E is an antioxidant and is involved in free radical chain reactions; it provides protection against free radical damage (Farina 2012; Takatsu 2009). B vitamins—notably B12 and folic acid—have a role in energy production and metabolism within the CNS. B vitamins have also been implicated in the production of nucleic acids; and the production and maintenance of myelin, essential for good neuronal health (Kühnast 2013; Osieczaga 2013; Pawlak 2014; Powers 2003; World Alzheimer Report 2014). Several clinical studies evaluated effect of vitamins on cognition. For example, a double-blind placebo RCT showed that 8 weeks' supplementation of multivitamin enhanced contextual recognition memory (a test of episodic memory) in older age men who are at risk of cognitive decline (Harris 2012). They indicated that contextual recognition memory is usually the first cognitive function to be damaged in the development of cognitive decline, mild cognitive impairment and Alzheimer’s disease (Harris 2012).

**Minerals:**

There are a number of minerals which appear to have some evidence for neuronal gene expression and the neuronal secretion of neurotransmitters (Ozawa 2012; Rossom 2012). Selenium was found to have some benefit in improving cognitive-cerebral function in older adults post chromium supplementation (Krikorian 2010; Smorgon 2004). Potassium, calcium, and magnesium were found to be protective in a cohort of Japanese participants (Ozawa 2012). Selenium may induce repair of DNA in damaged cells, and so limit growth of cancer cells. Selenium is a critical component of the enzyme glutathione peroxidase that detoxifies harmful molecules, making it especially important for cancer protection. As an antioxidant, selenium has been shown to protect the CNS and immune system from oxidative damage by harmful free radicals (Berr 2012; Mehdi 2013; Smorgon 2004).

**Why it is important to do this review**

The prevalence and financial implications of dementia are such that small effects on cognitive decline or on the incidence of dementia may have a large impact on healthcare costs and the overall burden of dementia. Robust assessments are needed of the effect size of interventions and of the ‘dose’ and duration of intervention necessary to achieve an effect.

For individuals, fear of cognitive decline and dementia may be powerful motivators to seek preventive interventions. Vitamin and mineral supplementation and cognitive activities (e.g. computerised ‘brain training’ games) in particular are subject to promotion by those with commercial interests. It is important for people to know whether time, effort and money they might invest to prevent cognitive decline is likely to be well spent. Information about adverse effects is also important. Although nutritional and
behavioural interventions are often perceived to be ‘low risk’, they are not necessarily without the potential to cause harm. For example, trials have found high doses of vitamin E to be associated with higher rates of side effects than placebo (Bjelakovic 2012; Brigelius-Flohe, 2007; Miller 2005).

**OBJECTIVES**

To evaluate the effects of vitamin and mineral supplementation on cognitive function in cognitively healthy people in late life.

**METHODS**

**Criteria for considering studies for this review**

**Types of studies**

We will include in the review randomised or quasi-randomised controlled trials, published or unpublished, reported in any language. We will include studies involving both randomised and non-randomised trial arms, but we will only consider results from the former. We may include crossover studies, but we will extract and analyse data from the first treatment period only. We will include trials irrespective of the length of follow-up after the intervention has finished; however, to be considered, trials need to report outcomes at at least one time point 12 weeks or more after randomisation. Trials in cognitively healthy people with a duration as short as 12 weeks will typically be investigating cognitive enhancement rather than maintenance of cognitive function. We will include these trials in order to give a full picture of the data, although it is recognized that the relationship between short-term cognitive enhancement and maintenance of cognitive function over longer periods of time is unclear.

**Types of participants**

We will include trial populations of cognitively healthy people in late life, i.e. participants aged 65 and over without a dementia diagnosis or cognitive impairment at baseline. We will only include trials using internationally accepted and validated instruments to assess cognitive function or dementia status at baseline.

The cognitive status of participants will be determined by the trialists’ own definitions of ‘cognitively healthy’. These definitions will be recorded.

Trials or subgroup analyses focusing on participants with ages of 65 years and older will be classified as ‘late life’ and will be considered in this review; data relating to those of ages ranging from 40 to 65 years will be classified as mid life and will be covered in a separate review (Denton 2015).

Where studies clearly state the age of participants among their inclusion criteria, this will be used as in the classification. If this is not available, the median and range or mean and standard deviation will be used to help place studies with a broad age range into the most appropriate review category. For example a study with an age range of 40 to 70, with a median of 50 years or less, will be considered mid life, whereas one with a median of 65 years or more would likely be categorised as late life.

We will contact trialists if further clarification is needed to determine health status or age. If there is no response then clinical experts in the respective review groups will classify the trials; or we will list these as ‘studies awaiting classification’.

**Types of interventions**

We will include studies comparing the effects of orally administered vitamin or mineral supplementation (or vitamin and mineral supplementation) with control interventions that are not expected to have specific risk-modifying effects. Treatment at any dose, whether as a single or a combination of interventions listed in Appendix 1, will be included. The minimum treatment duration is 12 weeks. The control arms would typically involve placebo or no intervention/usual care. Trials of vitamins or minerals (or vitamins and minerals) given in combination with other unrelated compounds (e.g. fatty acids, amino acids or medications) will be excluded unless the effects of individual components (minerals or vitamins) can be isolated. A trial evaluating the effects of vitamin A and C versus methionine would thus be excluded; whereas a trial evaluating vitamin A and C with methionine versus methionine only would be included.

**Types of outcome measures**

**Primary outcomes**

Mean overall cognitive functioning measured with any internationally accepted and validated measure: for example, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog); The Mini Mental State Examination (MMSE); Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); Cambridge Cognition Examination (CAMCOG).

The main time point of interest is end of trial, defined as the time point with the longest follow-up duration as measured from randomisation (see also section Data extraction and management). Outcome data reported at other time points after randomisation will be extracted and presented according to time points specified in the Data synthesis section.

**Secondary outcomes**

Secondary outcomes are any internationally accepted and validated measures of:

- specific cognitive functioning subdomain: episodic memory,
- specific cognitive functioning subdomain: executive functioning,
- specific cognitive functioning subdomain: speed of processing,
- quality of life, either generic or disease-specific,
- clinical global impression,
- functional performance,
- incidence of MCI or all-cause dementia,
- number of participants experiencing one or more serious adverse events (SAE)
- mortality.

Where studies include validated biomarkers (e.g. beta-amyloid or tau in cerebrospinal fluid, structural MRI or amyloid imaging) as well as cognitive outcomes, biomarker data will be extracted.
Outcomes to be included in the ‘Summary of findings’ table

Critical effectiveness outcomes, to be addressed in the ‘Summary of findings’ table for this review, will include all outcomes related to cognitive functioning, quality of life and mortality.

Search methods for identification of studies

Electronic searches

We will search ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane Dementia and Cognitive Improvement Group’s (CDCIG) specialised register.

ALOIS is maintained by the Trials Search Co-ordinator for the CDCIG, and contains studies that fall within the areas of dementia prevention, dementia treatment and management, and cognitive enhancement in healthy elderly populations. The studies are identified through:

1. Monthly searches of a number of major healthcare databases: MEDLINE, EMBASE, CINAHL, PsycINFO and LILACS;
2. Monthly searches of a number of trial registers: ISRCTN; UMIN (Japan’s Trial Register); the WHO portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others);
3. Quarterly search of The Cochrane Library’s Central Register of Controlled Trials (CENTRAL);
4. Six-monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses.

To view a list of all sources searched for ALOIS see About ALOIS on the ALOIS website (www.medicine.ox.ac.uk/alois).

Details of the search strategies run in healthcare bibliographic databases, used for the retrieval of reports of dementia, cognitive improvement and cognitive enhancement trials, can be viewed in the ‘methods used in reviews’ section within the editorial information about the Cochrane Dementia and Cognitive Improvement Group.

We will run additional searches in MEDLINE, EMBASE, PsycINFO, CINAHL, ClinicalTrials.gov and the WHO Portal/ICTRP to ensure that the searches for each suite of reviews is as comprehensive and as up to date as possible to identify published, unpublished and ongoing trials. The search strategy that will be used for the retrieval of reports of trials from MEDLINE (via the Ovid SP platform) can be seen in Appendix 2.

Searching other resources

We will screen reference lists of all included trials. In addition, we will screen reference lists of recent systematic reviews, health technology assessment reports and subject-specific guidelines identified through www.guideline.gov. The search will be restricted to those guidelines meeting NGC’s 2013 inclusion criteria published in this year or later.

We will contact experts in the field and companies marketing included interventions, in order to provide additional randomised trial reports that are not identified by the search.

Data collection and analysis

We will use this protocol alongside instructions for data extraction, quality assessment and statistical analyses, based on a generic protocol generated by the editorial board of CDCIG, to guide this and another 11 reviews on modifiable risk factors (see Acknowledgements).

Selection of studies

If multiple reports describe the same trial, we will include all to allow complete extraction of the trial details.

We will use crowdsourcing to screen the search results. Details of this have been described here: http://www.medicine.ox.ac.uk/alois/content/modifiable-risk-factors. In brief, teams of volunteers will perform a ‘first assess’ on the search results. The volunteers will be recruited through the author team’s institutions. They will screen the results using an online tool developed for Cochrane EMBASE project but tailored for this programme of work. The crowd will decide, based on a reading of title and abstract, whether the citation is describing a randomised or quasi-randomised trial, irrespective of the citations topic. It is estimated that this will remove 75% to 90% of results retrieved. The remaining results will then be screened by the author team.

Data extraction and management

Two review authors, working independently, will extract trial information using a standardised and piloted extraction method, referring also to a guidance document. Discrepancies will be resolved by discussion, or by the involvement of a third reviewer. Where possible, we will extract (as a minimum) the following information related to characteristics of participants, intervention and study design:

Participant characteristics

- gender
- baseline age (range, median, mean)
- education (level and years of education)
- baseline cognitive function
- cognitive diagnostic status
- duration of cognitive symptoms, if any
- ethnicity
- Apo-E genotype
- diabetes mellitus (yes/no)
- physical activity (as defined by the trialists)
- smoking (ever/never)

Intervention characteristics

- nature of the intervention; generic and trade name of intervention
- description of the control condition
- duration of treatment
- dosage and frequency
- any concomitant treatments
- treatment adherence

Methodological characteristics

Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life (Protocol)
• trial design (individual or cluster randomisation; parallel-group, factorial or crossover design)
• number of participants
• outcome measures used
• duration of follow-up as measured from randomisation
• duration of follow-up as measured from end of treatment
• source of financial support
• publication status

If cognitive outcomes data is available at multiple time-points within a given trial, we will group with cut-offs to describe immediate results (up to 12 weeks), short-term (up to 1 year), medium-term (1 to 2 years) and longer-term results (more than 2 years). For the secondary outcome all cause dementia, only outcome data at 1 year of follow-up or longer will be considered. Within these time periods, the longest available data reported by the study will be extracted (for example, if study reported data at 6 months, 9 months and 1 year, only the 1-year data will be extracted and analysed for the 1-year (short-term) time point.

For dichotomous outcomes (such as incident dementia or mortality), we will extract from each trial the number of participants with each outcome.

For continuous outcomes, we will extract the number of participants in whom the outcome was measured, and the mean and standard deviation of the change from baseline for each outcome at each time point. If change-from-baseline data are not available, we will extract the mean value at each time point. When necessary, means and measures of dispersion will be approximated from figures in the reports.

For crossover trials, we will extract data on the first treatment period only. Whenever possible, we will extract intention-to-treat data i.e. analysing all patients according to the group randomisation; if this is not available, then we will extract and report data from available case analyses. If these data are both not available, we will consider data from ‘per protocol’ analyses. We will contact the trialists if we cannot obtain the necessary data from the trial report.

Assessment of risk of bias in included studies

After completion of a standardised training session provided by AR, the risk of bias in each of the included trials will be assessed independently by one member of the author team and one experienced reviewer provided by the editorial team, using the Cochrane’s ‘Risk of bias’ tool (Higgins 2011). Disagreements will be resolved by consensus. We will assess the risk of bias potentially introduced by suboptimal design choices with respect to sequence generation, concealment of allocation, blinding of participants and care-givers, blinded outcome assessment, selective outcome reporting and incomplete outcome data, including the type of statistical analyses used (true intention-to-treat versus other). The general definitions that will be used are reported in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011); the review-specific definitions are described in Appendix 3 are in part derived from a previously published systematic review (Rutjes 2012).

Measures of treatment effect

The measure of treatment effect for continuous outcomes will be an effect size (standardised mean difference), defined as the between-group difference in mean values divided by the pooled standard deviation (SD). The treatment effect for dichotomous outcomes will be expressed as a relative risk (RR).

Unit of analysis issues

If cluster randomised trials are included, we aim to extract outcome data from analyses that take the effect of clustering into account (for example, an odds ratio with its confidence interval). When this is not possible, we will attempt to account for clustering by reducing the trial to its "effective sample size", dividing the original sample size by the design effect, as described in Section 16.3.4 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011; Rao 1992).

Dealing with missing data

Missing data in the individual trials may put the study estimates of effects at a high risk of bias, and may lower the overall quality of the evidence according to GRADE (Higgins 2011). We will deal with missing data in our ‘Risk of bias’ assessments and plan to evaluate attrition bias in stratified analyses of the primary outcomes (Appendix 3). We will thus analyse the available information and will not contact authors with a request to provide missing information, nor will we impute missing data ourselves.

Assessment of heterogeneity

Heterogeneity will be examined in stratified analyses by trial, participant and intervention characteristics, as outlined in Appendix 3.

Assessment of reporting biases

If a sufficient number of trials (at least 10) can be identified, we will use funnel plots with appropriate statistics to explore reporting biases and other biases related to small study effects (see also Data synthesis).

Data synthesis

Whenever possible, we will use standard inverse-variance random-effects meta-analysis to combine outcome data across the trials at end of trial (DerSimonian 1986); and, if possible, at least one additional time point (see Primary outcomes and Data extraction and management for definitions of time points). We will visually inspect forest plots for the presence of heterogeneity and will calculate the variance estimate tau² as a measure of between-trial heterogeneity (DerSimonian 1986). We pre-specify a tau² of 0.04 to represent low heterogeneity, 0.09 to represent moderate heterogeneity, and 0.16 to represent high heterogeneity between trials (Spiegelhalter 2004). The I² statistic and the corresponding Chi² test will be depicted in addition (Higgins 2003), to facilitate readers more familiar with this statistic. I² describes the percentage of variation across trials attributable to heterogeneity rather than chance, with values of 25%, 50%, and 75% typically being interpreted as low, moderate, and high between-trial heterogeneity. Tau² will be preferred over I² in the interpretation of between-trial heterogeneity, as the interpretation of I² can be largely affected by the precision of trials included in the meta-analysis (Rücker 2008). If sufficient trials (around 10) can be identified that contribute to the analyses of primary outcomes,
we will explore the association between trial size and treatment effects using funnel plots, where we plot effect sizes on the x-axis against their standard errors (SEs) on the y-axis (Moreno 2009; Sterne 2001). Funnel plot asymmetry will be assessed with the appropriate statistics for the metrics analysed (Higgins 2011). All P values are 2-sided. Statistical analyses will likely be done in Review Manager 5 (RevMan 2014); and in STATA, release 13 (StataCorp, College Station, Texas).

**Subgroup analysis and investigation of heterogeneity**

If around 10 or more trials are identified that contribute to the analyses of primary outcomes, we aim to perform stratified analyses of the primary effectiveness outcome, according to the following trial characteristics: concealment of allocation, blinding of patients, blinded outcome assessment, intention-to-treat analysis, trial size, type of control intervention, duration of treatment, and length of follow-up from randomisation (Appendix 3). We will use univariable random-effects meta-regression models as tests of interaction between treatment effect and these characteristics (Thompson 1999). The cut-off for trial size, treatment duration and follow-up duration are described in Appendix 3.

We will consider pooling interventions which have been postulated to share a main mechanism of action in preventing development of dementia. For example

- antioxidant properties—affecting superoxide dismutase (vitamin A, C, D, E, selenium)
- regulation/lowering levels of homocysteine: vitamins B12, folate and B6

Knowledge of possible mechanisms of actions is evolving, and we will consider other possible subgroups for data analysis as new information arises during the development of the review.

**Sensitivity analysis**

For each review, we will perform one sensitivity analysis for the primary effectiveness outcome, including high-quality trials only. High quality will be defined by the results of the stratified analyses, based on the statistically significant (P less than 0.05) interaction terms for methodological characteristics.

**GRADE and summary of findings table**

We will use GRADE to describe the quality of the overall body of evidence for each outcome in the 'Summary of findings' table (Higgins 2011; Guyatt 2008).

Quality is defined as the degree of confidence which can be placed in the estimates of treatment benefits and harms. There are four possible ratings: "high", "moderate", "low" and "very low". Rating evidence "high quality" implies that we are confident in our estimate of the effect, and further research is very unlikely to change this. A rating of "very low" quality implies that we are very uncertain about the obtained summary estimate of the effect.

The GRADE approach rates evidence from RCTs which do not have serious limitations as "high quality". However, several factors can lead to the downgrading of the evidence to "moderate", "low" or "very low". The degree of downgrading is determined by the seriousness of these factors: study limitations (risk of bias); inconsistency; indirectness of evidence; imprecision; and publication bias (Higgins 2011; Guyatt 2008).

**Acknowledgements**

This protocol is largely based on a general template constructed for the development of a larger series of protocols and reviews covered by a National Institute for Health Research (NIHR) Systematic Reviews Programme Grant. The common protocol covered four types of intervention, for which some evidence exists that these may modify the risk of developing cognitive impairments or dementia. These include vitamin or mineral supplementation (or vitamin and mineral supplementation), exercise, cognition, and dietary interventions. These interventions will each be evaluated each in three distinct populations: healthy mid life; healthy elderly/and those with mild cognitive impairment (MCI). The general protocol was inspired by a generic protocol approved by the Cochrane Musculoskeletal Group for another series of reviews (da Costa 2012; da Costa 2014; Nüesch 2009a; Reichenbach 2010; Rutjes 2009a; Rutjes 2009b; Rutjes 2010).
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life (Protocol)

Bjelakovic 2012
Bishop 2010
Berr 2012
Behl 1992
Bath 2013b
Annweiler 2012
Anderson 1997
Amanullah 2010

Additional references

Abraham 2015

Abraham RP, Denton DA, Rutjes AWS, Chong LY, Al-Assaf AS, Malik MA, Tabet N. Vitamin and mineral supplementation for prevention of dementia or delaying cognitive decline in people with mild cognitive impairment. Cochrane Database of Systematic Reviews 2015.

Amanullah 2010

Annweiler 2012

Bath 2013a

Bath 2013b

Behl 1992

Berr 2012

Bishop 2010

Bjelakovic 2012

Borchardt 1999

Brigelius-Flohe, 2007

Bruner 1996

Casserly 2004

Centers for Disease Control and Prevention 2014

Christa Maree Stephan 2013

Christensen 2013

Clarke 2007

da Costa 2012


References

knee or hip. The Cochrane database of systematic reviews 2014;9:CD003115. [PUBMED: 25229835]

Delage 2014 (accessed 21 September 2015)

DeLuca 1975

Denton 2015

Depp 2012

DerSimonian 1986

Dolphin 2012

Duara 2011

Dysken 2014

Farina 2012

Ferland 2012

Ferland 2013

Guyatt 2008

Halliwell 1992

Halliwell 1999

Harris 2012

Hendrie 2006

Higgins 2003

Higgins 2011

Institute of Medicine 2011

Jeandel 1989

Jellinger 2006

Kaden 2011
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life (Protocol)
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life (Protocol)

O’Leary 2012

O’Sullivan 2001

ODS 2014

Ogawa 1994

Ono 2012

Osiezagha 2013

Ozawa 2012

Packer 1997

Pawlak 2014

Perrig 1997

Petersen 1999

Powell 2000

Powers 2003

Preuss 1997

Przybelski 2007

Rahman 2007

Rao 1992

Reichenbach 2010

Reiter 1995

RevMan 2014 [Computer program]

Rossom 2012

Rutjes 2009a

Rutjes 2009b

Rutjes 2010
Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD003132.pub2; PUBMED: 20091539]

Rutjes 2012

Rücker 2008

Savva 2009

Scott 2013

Smorgon 2004

Sodhi 2013

Spiegelhalter 2004

Stephan 2007

Sterne 2001

Tabet 2001

Tabet 2002

Takatsu 2009

Thompson 1999

van den Berg 2012

van der Flier 2005

van der Schaft 2013

Wang 2000

WHO 2012

Wilson 2002

World Alzheimer Report 2014
## APPENDICES

### Appendix 1. Biological Plausibility of Vitamins and Minerals

<table>
<thead>
<tr>
<th>Supplement*</th>
<th>Route</th>
<th>Biological plausibility</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitamins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin A</td>
<td>anti-oxidant;</td>
<td>Carboxylic form of Vitamin A known as all-trans retinoic acid has been shown to have memory restorative function and it may be attributed to its anti-cholinesterase, anti-oxidative and anti-inflammatory potential (Sodhi 2013). Vitamin A and beta-carotene may also inhibit the formation, extension and destabilising effects of beta-amyloid fibrins. Plasma or cerebrospinal fluid concentrations of vitamin A and beta-carotene have been reported to be lower in AD patients, and increased Vit A/beta carotene concentrations have been clinically shown to slow the progression of dementia (Ono 2012).</td>
</tr>
<tr>
<td></td>
<td>anti-inflammatory;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>anti-cholinesterase;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>beta-amyloid inhibition</td>
<td></td>
</tr>
<tr>
<td>Vitamin D</td>
<td>neuronal activity</td>
<td>Vitamin D receptor (VDR) and 1, alpha-hydroxylase, the terminal calcitriol-activating enzyme, are distributed throughout both the foetal and adult brain. This is thought to play a role in brain development and critical brain functions (McCann 2008). Significant correlation between serum 25(OH)D levels and cognitive scores were reported in DeLuca 1975 and Przybelski 2007.</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>anti-oxidant;</td>
<td>Vitam in E consists of a group of tocopherols and tocotrienols. Apart from lipid anti-oxidant activity, other functions include membrane stabilisation by forming complexes with the products of lipid hydrolysis (Wang 2000). It has been shown that the antioxidant and free radical scavenging activity of Vitamin E inhibits amyloid beta protein induced neuronal cell death and may have implication in prevention and treatment of Alzheimer’s dementia (Behl 1992).</td>
</tr>
<tr>
<td></td>
<td>beta-amyloid inhibition</td>
<td></td>
</tr>
<tr>
<td>Vitamin K</td>
<td>neuronal activity</td>
<td>Vitamin K participates in the synthesis of sphingolipids. Sphingolipids participate in important cellular events such as proliferation, differentiation, senescence and cell-cell interactions. Sphingolipid metabolism has been linked to age-related cognitive decline and neurodegenerative diseases such as Alzheimer’s disease (Ferland 2012). A cross-sectional study found correlations between higher serum phylloquinone concentration and better cognitive scores in tests evaluating episodic verbal memory among healthy older adults (Ferland 2013).</td>
</tr>
<tr>
<td>Thiamine</td>
<td>neuronal activity</td>
<td>Thiamine is required as a cofactor in the cellular production of energy and enhances normal neuronal activities (Osiezagha 2013). Rats with an episode of induced thiamine deficiency had cognitive, learning and memory impairments (Langlais 1995).</td>
</tr>
<tr>
<td>(Vitamin B1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Riboflavin</td>
<td>neuronal activity</td>
<td>Riboflavin (7,8-dimethyl-10-ribityl-isalloxazine) is water soluble. Symptoms of neurodegeneration and peripheral neuropathy in riboflavin deficiency have been documented in animal studies, but not observed in humans. Subclinical riboflavin deficiency may contribute to increased concentrations of plasma homocysteine and may be associated with increased risk of cardiovascular disease and impaired handling of iron (Powers 2003).</td>
</tr>
<tr>
<td>(Vitamin B2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niacin</td>
<td>vascular:</td>
<td>Niacin is a water-soluble precursor cofactor essential for the formation of dozens of enzymes. Niacin decreases atherosclerosis development mainly by reducing LDL cholesterol. It also has modest HDL-cholesterol-raising and anti-inflammatory effects (Kühnast 2013). Niacin deficiency causes pellagra. Its neuropsychiatric symptoms are similar to those in Alzheimer’s disease or vascular dementia (Amanullah 2010).</td>
</tr>
<tr>
<td>(Vitamin B3)</td>
<td>anti-inflammatory</td>
<td></td>
</tr>
</tbody>
</table>
Vitamin B6 is a group of water-soluble compounds (vitamers). Pyridoxal 5' phosphate (PLP) and pyridoxamine 5' phosphate (PMP), Pyridoxine 5'-phosphate (PNP))

Vitamin B6 has many important brain functions such as biosynthesis of neurotransmitters (GABA, dopamine, noradrenaline, serotonin), receptor binding, macronutrient metabolism, and gene expression. In a study looking at low plasma B6 levels predicting cognitive decline and depression in at-risk individuals, low PLP status was seen as a risk factor for cognitive decline and depression in at-risk populations (Scott 2013).

Folate is a cofactor and promotes the remethylation of homocysteine -- an amino acid that can induce DNA strand breakage, oxidative stress and apoptosis. Folate is required for normal development of the nervous system, playing important roles regulating neurogenesis and programmed cell death. Folate deficiency and its resultant increase in homocysteine levels has been linked to several neurodegenerative conditions, including stroke, Alzheimer’s disease and Parkinson’s disease (Mattson 2003).

Vitamin B12 acts as a coenzyme in metabolism of amino acids and fatty acids required for the synthesis of nucleic acids, erythrocytes and in the maintenance of myelin (Pawlak 2014). Lower vitamin B12 status has been associated with increased rates of cognitive decline and dementia (Clarke 2007; O’Leary 2012).

Pantothenic acid (PA) is a component of coenzyme A, an essential cofactor in fatty acid oxidation, lipid elongation, and fatty acid synthesis (Kelly 2011). This may have an indirect effect in cognition.

Biotin is also known as Vitamin H and is part of the B complex group of vitamins. They act as cofactors in carboxylase enzymes, fatty acid, and amino acid metabolism. This may have an indirect effect in cognition.

Vitamin C has antioxidant functions and is required for the synthesis of noradrenaline from dopamine. It has been reported that Vitamin C levels have been lower than controls in patients with senile dementia of Alzheimer’s type (Jeandel 1989). In a longitudinal and cross-sectional study it was found that higher vitamin C levels were associated with better memory performance (Perrig 1997).

Calcium ions regulate a number of physiological processes including neuronal gene expression and the neuronal secretion of neurotransmitters (Dolphin 2012; Delage 2014 (accessed 21 September 2015)). Supplementation with calcium together with vitamin D was found to have no significant association with incident cognitive impairment (Rossom 2012).

Ozawa 2012 concluded that, in the general Japanese population, higher self-reported dietary intakes of potassium, calcium, and magnesium reduced the risk of all-cause dementia, especially Vascular Dementia (VaD). The proposed mechanism was through the reduction of of vascular risk factors.

Chromium is needed for energy production and has been found to promote the effect of insulin involved in metabolism and storage of protein, carbohydrates and lipids within the CNS (Institute of Medicine 2011; Ozawa 2012; Anderson 1997). Chromium is involved in metabolism of nucleic acid, which is needed to build DNA, the genetic material in cells; and promotes synthesis of cholesterol and fatty acids needed for brain function. It may lower LDL cholesterol and triglyceride levels, raise
(Continued)

HDL cholesterol levels and reduce high blood pressure (Preuss 1997), hence may affect vascular risk factors.

Insulin resistance is implicated in the pathophysiological changes associated with Alzheimer’s disease, and pharmaceutical treatments that overcome insulin resistance improve memory function in subjects with mild cognitive impairment (MCI) and early Alzheimer’s disease. Chromium (Cr) supplementation improves glucose disposal in patients with insulin resistance and diabetes. A double blind RCT suggested that supplementation with Chromium picolinate can enhance cognitive inhibitory control and cerebral function in older adults at risk for neurodegeneration (Krikorian 2010). An additional study reported a positive correlation between cognitive function and serum chromium levels (Smorgon 2004).

Copper antioxidant

Copper is a component of an antioxidant enzyme called superoxide dismutase that protects cells from damage by harmful free radicals. Copper is necessary for a healthy nerve system and taste sensitivity (Institute of Medicine 2011).

Copper may promote non-amyloidogenic processing of amyloid precursor protein (APP) and thereby lower the Aβ production in cell culture systems, and it increases lifetime and decreases soluble amyloid production in APP transgenic mice (Borchardt 1999). In Alzheimer patients, a decline of Aβ levels in CSF is reported in adults in the treatment group (Kaden 2011).

Iodine neuronal development and structure.

Iodine is needed for the synthesis of thyroid hormones which, in turn, are needed for the myelination of the central nervous system. Iodine is necessary for the normal development of the brain. A deficiency of this mineral during critical periods of development in gestation can lead to intellectual disability and neurodevelopmental problems (Bath 2013a). Positive association was found between maternal iodine status and child IQ at age 8 years and reading ability at age 9 years (Bath 2013b).

Iron neuronal activity

Iron is needed for development of oligodendrocytes and numerous enzymes that synthesise neurotransmitters such as noradrenaline, serotonin, and dopamine. It is important for production of the haemoglobin in red blood cells (Delage 2014 (accessed 21 September 2015); Institute of Medicine 2011). Regression analysis showed that non-anaemic iron-deficient adolescent girls who received iron performed better on a test of verbal learning and memory than girls in the control group (Bruner 1996).

Magnesium energy, metabolism

Magnesium is involved in hundreds of enzyme reactions, including protein synthesis. It plays a role in energy production; can improve insulin sensitivity in diabetics; helps regulate blood sugar level; and regulates neuro-muscular transmission.

Higher self-reported dietary intakes of potassium, calcium, and magnesium have been reported to reduce the risk of all-cause dementia, especially VaD, in the general Japanese population (Ozawa 2012).

Manganese metabolism

Manganese is needed to synthesise fatty acids and cholesterol, and metabolise carbohydrates and proteins. It is important for energy production. It promotes utilisation of other key nutrients like vitamin B1 (thiamine), biotin, choline, ascorbic acid, and vitamin E (Delage 2014 (accessed 21 September 2015)).

Manganese is needed for glucose metabolism, which helps regulate blood glucose. It is needed to make manganese superoxide dismutase (MnSOD), one of the key antioxidants that protects cells from free radical damage, and so helps maintains healthy nerves. It works synergistically with the B-complex vitamins to generate an overall feeling of well-being (Institute of Medicine 2011).

Molybdenum metabolism

Molybdenum promotes normal cell function; and functions as a cofactor for three essential enzymes that play a vital role in carbohydrate metabolism, utilisation...
of iron, sulphite detoxification, and uric acid formation (Delage 2014 (accessed 21 September 2015); Institute of Medicine 2011).

Phosphorus
metabolism, neuronal structure and function.
Phosphorus is needed for metabolism of carbohydrates and fats to produce energy and is involved in the production of ATP required for growth and repair of cells and tissues; needed to make cell membranes. It helps the body utilise the B-complex vitamins that support proper muscle and nerve function (Delage 2014 (accessed 21 September 2015); Institute of Medicine 2011).

Potassium
nerve transmission.
Potassium is involved in regulating nerve transmissions and muscle contractions. It helps the body handle sodium and so reduces the risk of high blood pressure (Berr 2012). It has been found to lower the risk of stroke and ischaemic heart disease. Potassium is needed for synthesis of protein from amino acids (Delage 2014 (accessed 21 September 2015); Institute of Medicine 2011).

Higher self-reported dietary intakes of potassium, calcium, and magnesium reduce the risk of all-cause dementia, especially VaD, in the general Japanese population (Ozawa 2012).

Selenium
antioxidant.
Selenium is an important antioxidant especially in combination with vitamin E, in the central nervous system and other body tissues (Delage 2014 (accessed 21 September 2015); Mehdi 2013; Rahman 2007).

Low selenium levels were found to be associated with poorer cognitive function (Berr 2012; Smorgon 2004). Supplementation with selenium has been associated with improved overall health, reducing oxidative stress and reducing the risk of dementia (Mehdi 2013).

Zinc
anti-oxidant neuronal activity
Zinc is a constituent of the antioxidant enzyme superoxide dismutase that helps reduce the harm from free radicals. Zinc regulates cell division and synthesis of genetic cell DNA. It is essential for reproduction, repair, and normal growth within the CNS (Delage 2014 (accessed 21 September 2015)).

Zinc is found in high levels in the brain where it performs catalytic, structural and regulatory roles in cellular metabolism. Zinc is bound to proteins but free zinc is present in synaptic vesicles and performs a role in neurotransmission mediated by glutamate and gamma-aminobutyric acid (GABA). Short-term deficits of zinc have been shown to impair certain measures of mental and neurological function while long-term deficits of zinc, especially during gestation, result in malformation or deficits in attention, learning, memory and neuropsychological behaviour (Institute of Medicine 2011)

Zinc was found to be capable of reducing post-ischaemic injury to a variety of tissues and organs through a mechanism that might involve the antagonism of copper reactivity. Although the evidence for the antioxidant properties of zinc is compelling, the mechanisms are still unclear (Powell 2000).

* Only orally-administered supplements taken at any dose for at least 12 weeks are considered. Supplements that combine vitamins or minerals are eligible as well.

Appendix 2. MEDLINE Search Strategy
1. exp *Vitamins/
2. exp *Minerals/
3. exp *Dietary Supplements/
4. Calcium Carbonate/
5. vitamin*.ti,ab.
6. cholecalciferol.ti,ab.
7. ergocalciferol.ti,ab.
8. toxiferol.ti,ab.
9. retinol.ti,ab.
10. "retinoic acid".ti,ab.
11. Vitamin A/
12. Vitamin B12/
13. Vitamin D/
14. Vitamin E/
15. "beta-carotene".ti,ab.
17. "gamma-carotene".ti,ab.
18. "beta-cryptoanthin".ti,ab.
19. thiamine.ti,ab.
20. riboflavin.ti,ab.
21. niacin.ti,ab.
22. nicotinamide.ti,ab.
23. pantothentic.ti,ab.
24. pyridoxine.ti,ab.
25. pyridoxal.ti,ab.
26. pyridoxamine.ti,ab.
27. biotin.ti,ab.
28. "folic acid".ti,ab.
29. Folic Acid/
30. cyanocobalamin.ti,ab.
31. methylcobalamin.ti,ab.
32. "L-ascorbic acid".ti,ab.
33. "ascorbic acid".ti,ab.
34. ascorbate.ti,ab.
35. Ascorbic Acid/
36. phylloquinone.ti,ab.
37. phytomeadione.ti,ab.
38. phytonadione.ti,ab.
39. mineral*.ti,ab.
40. multivitamin*.ti,ab.
41. "diet* supplement*".ti,ab.
42. calcium.ti,ab.
43. Calcium/
44. iron.ti,ab.
45. zinc.ti,ab.
46. sodium.ti,ab.
47. potassium.ti,ab.
48. phosphorus.ti,ab.
49. magnesium.ti,ab.
50. chloride.ti,ab.
51. sulphur.ti,ab.
52. manganese.ti,ab.
53. cobalt.ti,ab.
54. selenium.ti,ab.
55. copper.ti,ab.
56. iodine.ti,ab.
57. fluoride.ti,ab.
58. or/1-57
59. "Aging/ 
60. Aged/ 
61. "Aged, 80 and over"/
62. Middle Aged/
63. Age Factors/
64. "mild cognitive impairment".ti,ab.
65. Mild Cognitive Impairment/
Appendix 3. Definitions of design, patient and intervention characteristics as applied in the stratified analyses exploring between trial variations in intervention effect
<table>
<thead>
<tr>
<th>Item</th>
<th>Definition</th>
</tr>
</thead>
</table>
| **Bias related characteristics**               | **Concealment of allocation (avoiding selection bias)**: The guidance from the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) will be used to judge bias related to sequence generation and concealment of allocation using the two Cochrane 'Risk of bias' items. From these, the statistician will derive a single variable to be used in the stratified analysis: allocation concealment will be judged at low risk of bias if the investigators responsible for patient selection were unable to suspect before allocation which treatment was next. Concealment will downgraded to high risk of bias if there is evidence of inadequate sequence generation.  
  
  **Blinding of patients and personnel (avoiding performance bias)**: Low risk of bias will be judged if:  
  - a credible sham procedure was used; or if a placebo supplement or pill was used that was reported to be identical in appearance to the experimental intervention and the specific outcome or group of outcomes is/are likely to be influenced by lack of blinding  
  - blinding is absent or suboptimal and the specific outcome, such as mortality, is not likely to be influenced by lack of blinding  
  
  **Blinding of outcome assessment (avoiding detection bias)**: For self-reported/partner reported outcomes: Low risk of bias will be judged if:  
  - self-reported outcomes were assessed AND blinding of patients was considered adequate AND there was no information to suggest that there was an investigator involved during the process of outcome assessment; OR if blinding of investigators performing the outcome assessment was reported AND an attempt to blind patients was reported.  
  For other outcomes: Outcome assessment was considered to be blinded if the outcome assessment was reported to be blinded.  
  
  **Statistical Analyses (avoiding attrition bias)**: For continuous outcomes Low risk of bias will be judged if:  
  - at least 90% of the patients randomised were analysed AND the difference in percentage of participants not analysed was 5% or lower across trial arms,  
  - for trials using imputations to handle missing data: the percentage of participants with missing data did not exceed 20% AND the difference in percentage of participants with imputed data was 10% or lower across trial arms AND applied imputation methods were judged to be appropriate.  
  For binary outcomes of rare events Low risk of bias will be judged if:  
  - the event rate is low (e.g. incidence of dementia) AND at least 95% of the patients randomised were analysed AND there is no evidence of differential reasons for missing data that may alter the estimate AND the rate of missing data does not exceed the expected event rates.  
  For binary outcomes of non-rare events Low risk of bias will be judged if:  
  - at least 90% of the patients randomised were analysed AND the difference in percentage of participants not analysed was 5% or lower across trial arms AND there is no evidence of differential reasons for missing data that may alter the estimate AND the rate of missing data does not exceed the expected event rates.  
  
  **Trial Size**: A large trial will be defined by a sample size calculation for the primary outcome.  
  
  **Follow-up duration**: For the cognitive outcomes we will group studies according to these follow up cut-offs to describe immediate results (up to 12 weeks), short-term (up to 1 year), medium-term (1 to 2 years) and longer term results (more than 2 years). For the secondary outcome all-cause dementia, only outcome data at 1 year of follow-up or longer will be considered and therefore the grouping will include short-term (1 year), medium-term (up to 2 years) and longer-term results (more than 2 years).  

| Treatment related characteristics | |
Treatment duration

The minimum treatment duration of 3 months is considered short term, 3 to 12 months as medium term, and 12 months for long term.

Dose of treatment

Treatment will be analysed as high dose vs low dose according to previously reported cut-offs.

Mechanisms of action of the supplements**

Supplements postulated to share a main mechanism of action in preventing development of dementia, including:

- Antioxidant properties - affecting superoxide dismutase (vitamin A, C, D, E, selenium)
- Regulation/lowering levels of homocysteine: vitamins B12, folate and B6

Participant-related characteristics

Cognition-related criteria

No risk of deficiency vs at risk of deficiency for the type of vitamin and minerals investigated (e.g. presence of malabsorptive diseases, malnutrition, comorbidities or concomitant medications, and ethnicity (Vitamin D))

* The descriptions depicted in this Table are in addition to the guidance provided by Cochrane (Higgins 2011).

** Knowledge of possible mechanisms of actions is evolving, and we will consider other possible subgroups for data analysis as new information arises during the development of the review.

CONTRIBUTIONS OF AUTHORS

Completion of the protocol: Al-Assaf AS, Denton DA, Abraham RP, Rutjes AWS, Chong LY, Anderson J, Malik MA, Tabet N.
Completion of the searches: Noel-Storr A.
Screening of references: Al-Assaf AS, Denton DA, Abraham RP, Anderson J, Malik MA, Tabet N.
Acquisition of data: Al-Assaf AS, Denton DA, Abraham RP, Anderson J, Malik MA, Tabet N.
Risk of bias assessments and GRADE-ing: Al-Assaf AS, Denton DA, Abraham RP, Rutjes AWS, Chong LY, Anderson J, Malik MA, Tabet N
Statistical analysis: Al-Assaf AS, Denton DA, Abraham RP, Rutjes AWS, Chong LY, Anderson J, Malik MA, Tabet N
Overall interpretation of data: Al-Assaf AS, Denton DA, Abraham RP, Rutjes AWS, Chong LY, Anderson J, Malik MA, Tabet N

DECLARATIONS OF INTEREST

Al-Assaf AS: none known
Denton DA: none known
Abraham RP: none known
Rutjes AWS: none known
Chong LY: none known
Anderson JL: none known
Malik MA: none known
Tabet N: none known
SOURCES OF SUPPORT

Internal sources

• No sources of support supplied

External sources

• NHS, UK, Other.

This protocol/review was supported by the National Institute for Health Research, via a Cochrane Programme Grant to the Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.